Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2024.03.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Shijing Jia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: sjia@med.umich.edu. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Biomarkers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: Iron deficiency (ID) is a common extrapulmonary manifestation in cystic fibrosis (CF). CF transmembrane conductance regulator (CFTR) modulator therapies, particularly highly-effective modulator therapy (HEMT), have drastically improved health status in a majority of people with CF. We hypothesize that CFTR modulator use is associated with improved markers of ID. METHODS: In a multicenter retrospective cohort study across 4 United States CF centers 2012-2022, the association between modulator therapies and ID laboratory outcomes was estimated using multivariable linear mixed effects models overall and by key subgroups. Summary statistics describe the prevalence and trends of ID, defined a priori as transferrin saturation (TSAT)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: sjia@med.umich.edu.
- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
- Department of Internal Medicine, Maine Medical Center, Tufts University, Portland, ME, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
- Departments of Internal Medicine and Pediatrics, National Jewish Health, Denver, CO, USA; Departments of Internal Medicine and Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Förderung
- NHLBI NIH HHS
- Cystic Fibrosis Foundation
Zitieren
APA
Jia, S., Wang, Y., Ross, M. H., Zuckerman, J. B., Murray, S., Han, M. K., Cahalan, S. E., Lenhan, B. E., Best, R. N., Taylor-Cousar, J. L., Simon, R. H., Fitzgerald, L. J., Troost, J. P., Sood, S. L., & Gifford, A. H. (2024). Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.03.002
Vancouver
Jia S, Wang Y, Ross MH, Zuckerman JB, Murray S, Han MK, et al. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.03.002
BibTeX
@article{Jia2024,
author = {Jia, Shijing and Wang, Yizhuo and Ross, Melissa H and Zuckerman, Jonathan B and Murray, Susan and Han, MeiLan K and Cahalan, Shannon E and Lenhan, Blair E and Best, Ryan N and Taylor-Cousar, Jennifer L and Simon, Richard H and Fitzgerald, Linda J and Troost, Jonathan P and Sood, Suman L and Gifford, Alex H},
title = {Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2024.03.002}
}
EUVIMED